Cancer Immunology, Immunotherapy

, Volume 57, Issue 10, pp 1523–1529

Combined modality immunotherapy and chemotherapy: a new perspective

  • Rupal Ramakrishnan
  • Scott Antonia
  • Dmitry I. Gabrilovich
Symposium Paper

DOI: 10.1007/s00262-008-0531-4

Cite this article as:
Ramakrishnan, R., Antonia, S. & Gabrilovich, D.I. Cancer Immunol Immunother (2008) 57: 1523. doi:10.1007/s00262-008-0531-4
  • 290 Downloads

Abstract

The results of recent clinical trials have demonstrated that cancer vaccines continue to struggle to achieve tangible clinical benefits as monotherapy. Tumor-induced abnormalities in the immune system hamper anti-tumor T cell responses limiting the effectiveness of cancer immunotherapy. Recently, evidence has been mounting to suggest that immunotherapy has the possibility of achieving better success when used in combination with conventional chemotherapy. In clinical trials, immune responses elicited by cancer vaccines appear to augment the effectiveness of subsequent conventional cancer therapies.

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Rupal Ramakrishnan
    • 1
  • Scott Antonia
    • 1
  • Dmitry I. Gabrilovich
    • 1
  1. 1.H. Lee Moffitt Cancer Center and Research InstituteTampaUSA